Biologically Active Substance
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.
Attovia Secures $105M for Multiple Trials of Innovative Industrial and Institutional Biologics
Attovia, biologics, industrial and institutional (I&I), crossover investors, funding, clinical trials
Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits
CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.
Prologue Ventures: Revolutionizing Viral Protein Drug Development with $50 Million Investment
Prologue Ventures, viral protein drugs, $50 million investment, drug development, biotechnology, healthcare innovation.
What is the difference between prime editing and CRISPR/Cas9
The difference between Prime Editing and CRISPR/Cas9 lies in their mechanisms of editing DNA, their efficiency, precision, and the types of genetic modifications they can achieve. Mechanism of Editing Efficiency and Precision Types of Genetic Modifications In summary, while both Prime Editing and CRISPR/Cas9 are groundbreaking genome editing tools, Prime Editing offers a more precise […]
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.
BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges
BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development
AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline
AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor
Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce
Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer